# NCT04820023 (NCT04820023)

> Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

No report yet. It can be ordered.

- Drugs tested: BBT-176
- Indication: advanced NSCLC with progression after EGFR TKI treatment

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04820023
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Bridge Biotherapeutics, Inc.
- Conditions: NSCLC
- Interventions: BBT-176, QD; BBT-176, BID
- Enrollment: 45
- Primary outcome: (Part 1) Incidence of Adverse Events and Clinical Laboratory Abnormalities Defined as Dose-limiting Toxicities (DLTs)
- Primary outcome: (Part 2) Objective Response Rate (ORR)

## Indexed commentary on NCT04820023 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04820023